The drug, to be sold under the brand Leqembi, belongs to a  class of treatments that aims to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic brain protein known as beta amyloid. Nearly all previous experimental drugs using the same approach had failed.Initial access to the drug likely will be limited by a number of factors including reimbursement decisions from Medicare, the U.S. government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi. (Reporting by Deena Beasley in Los Angeles and Bhanvi Satija in Bengaluru; Editing by Bill Berkrot)